Summary
Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral abuse-deterrent formulation of ER morphine sulfate tablets (morphine ARER [abuse-resistant extended-release], MorphaBondTM ER) resists physical manipulation and chemical extraction, forms a nonsyringeable material in liquid environments, and retains its ER characteristics despite manipulation. Morphine ARER is formulated with multiple overlapping physiochemical barriers instead of antagonists or aversive agents to deter misuse and abuse. When crushed and taken intranasally, morphine ARER has a 40% lower mean maximum drug-liking score than crushed intranasal morphine ER.
Register to download
Pharmacokinetic Charcateristic of Oral_Intranasal Morphine ARER
You may also be interested in:
Case Study
Recruiting Solid Tumor Patients in a Complex ADME Trial
PRA's PPS facility in Budapest (PPS-Hungary) was contracted to run an open-label, non-randomized, Phase I study to characterize the mass balance and…
Fact Sheet
Vaccine Solutions
PRA’s Vaccine Solutions group understands the unique challenges and characteristics of vaccine development. Right from the start, our experts will…
White Paper
Favorable Regulatory Procedures In The Netherlands Phase I-IIa
The EU Clinical Trials Directive (CTD) has been fully implemented in The Netherlands. Prior to beginning a clinical trial, an identical Clinical…